Clinical trials: psoriasis
Plaque Psoriasis
Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate
The aims is to evaluate the efficacy and comparative isolation of the association Mometasone furoate + Salicylic Acid and the substance isolated Mometasone furoate produced by the Laboratory Glenmark Pharmaceuticals Ltd.
- Trial name
- Psoriasis (NCT01228656)
- Testing
- mometasone furoate + salicylic acid, Mometasone furoate
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Mild to Moderate Psoriasis
Topical Application of AS101 for the Treatment of Psoriasis
This protocol relates to a phase II randomized double blind, placebo controlled study of the AS101 topical application for the treatment of mild to moderate Psoriasis.
- Trial name
- NCT00788424
- Testing
- AS101 Cream
- Where
- Israel
- Sponsor
- BioMAS Ltd
Psoriasis
Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen
This study is conducted to assess the relative bioavailability of MTX administered subcutaneously via a prefilled pen (50mg/mL) compared with MTX administered via IM injection (25mg/mL).
- Trial name
- NCT02097173
- Testing
- Methotrexate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- medac GmbH
Psoriasis
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
The purpose of this study is to explore the efficacy and safety of multiple, escalating doses of ASP015K when compared to placebo in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT01096862
- Testing
- peficitinib
- Where
- 11 sites in United States
- Volunteers
- 124 people
- Sponsor
- Astellas Pharma Inc
Psoriasis
Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis
This study will provide a direct comparison of 'continuous therapy' and 'intermittent therapy' with withdrawal and retreatment upon return of psoriasis.
- Trial name
- NCT00195507
- Testing
- Etanercept
- Where
- 127 sites in Austria, Belgium and 17 more
- Volunteers
- 720 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Plaque Psoriasis
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
- Trial name
- NCT00691964
- Testing
- ABT-874, etanercept
- Where
- 35 sites in United States
- Volunteers
- 347 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.
This study was designed to prove and quantify the hypothesis that secukinumab is effective, safe and well tolerated in the treatment of moderate to severe chronic plaque-type psoriasis in patients who are inadequate responders to…
- Trial name
- SIGNATURE (NCT01961609)
- Testing
- Secukinumab (AIN457)
- Where
- 54 sites in Ireland, United Kingdom
- Volunteers
- 235 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Study to Investigate the Efficacy and the Safety of M518101 in Psoriasis Patients
This study is to investigate the efficacy and safety of M518101 in male and female plaque psoriasis patients with refractory plaques.
- Trial name
- NCT00884169
- Testing
- M518101
- Where
- United Kingdom
- Sponsor
- Maruho Co., Ltd.
Psoriasis
Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis
This study is a randomized, double-blind, multi-center, parallel, phase II clinical trial, aiming to evaluate the efficacy and safety of SHR-1139 injection for adult patients with psoriasis.
- Trial name
- NCT07719530
- Testing
- The SHR-1139 injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Inverse Psoriasis, Sebopsoriasis
Efficacy of Aerosal® in the Treatment of Inverse Psoriasis and Sebopsoriasis
The purpose of this study is to evaluate the efficacy of Aerosal® compared to placebo in the prognosis of inverse psoriasis or sebopsoriasis present for at least one year
- Trial name
- NCT01574872
- Testing
- Halotherapy
- Where
- Italy
- Sponsor
- Tecno Sun SRL
Palmoplantar Pustulosis
A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
A 12-week Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis followed by an Open-label Extension Phase.
- Trial name
- NCT05194839
- Testing
- RIST4721
- Where
- 51 sites in United States, Canada and 5 more
- Volunteers
- 79 people
- Sponsor
- Aristea Therapeutics, Inc.
Plaque Psoriasis Vulgaris
Bioavailability of AZD0284 and IV Microtracer Study
The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.
- Trial name
- NCT03029741
- Testing
- AZD0284, [14C]AZD0284
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Psoriasis Vulgaris
Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling
The purpose of this study is to collect skin biopsies and non-invasive microneedle device samples from participants with mild chronic plaque psoriasis vulgaris to use for transcriptomics profiling for further investigation.
- Trial name
- NCT03795402
- Testing
- Microneedle Device
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis
The aim of the study is to intra-individually compare the dose-related efficacy of LAS41004 in a Psoriasis Plaque Test (PPT)
- Trial name
- NCT01119339
- Testing
- LAS 41004, LAS 41004 dosage 6, Reference
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Almirall, S.A.
Psoriasis
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
To evaluate the efficacy and to compare efficacy and safety of BI 695501 versus Humira in patients with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT02850965
- Testing
- BI 695501, Humira
- Where
- 54 sites in United States, Czechia and 6 more
- Volunteers
- 318 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin.
- Trial name
- OptIMMize-1 (NCT04435600)
- Testing
- Risankizumab, Ustekinumab
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 139 people
- Sponsor
- AbbVie
Psoriasis
Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis.
- Trial name
- NCT02801435
- Testing
- 0.5% Icotinib hydrochloride cream, 1.0% Icotinib hydrochloride cream, 2.0% Icotinib hydrochloride cream
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Psoriasis, Plaque Psoriasis
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis when administered every 2 weeks.
- Trial name
- CIMPASI-1 (NCT02326298)
- Testing
- Certolizumab Pegol
- Where
- 30 sites in United States, Canada and 3 more
- Volunteers
- 234 people
- Sponsor
- UCB Biopharma S.P.R.L.
Generalized Pustular Psoriasis
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
- Trial name
- GEMINI-1 (NCT05352893)
- Testing
- 750 mg Imsidolimab, 300 mg Imsidolimab
- Where
- 65 sites in United States, Australia and 13 more
- Volunteers
- 45 people
- Sponsor
- Vanda Pharmaceuticals
Plaque Psoriasis Subjects
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis.
Phase III Efficacy and Safety Study of RSS0393 Ointment in Plaque Psoriasis.
- Trial name
- NCT07543224
- Testing
- RSS0393 ointment 0.03%
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Reistone Biopharma Company Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.